ANDAINJECTIONINJECTABLE
Approved
Jun 2004
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
DIMENHYDRINATE (dimenhydrinate) by Fresenius Kabi is clinical pharmacology while the precise mode of action of dimenhydrinate is not known, it has a depressant action on hyperstimulated labyrinthine function. First approved in 2004.
Drug data last refreshed 20h ago
Mechanism of Action
CLINICAL PHARMACOLOGY While the precise mode of action of dimenhydrinate is not known, it has a depressant action on hyperstimulated labyrinthine function.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin
Started Nov 2016
292 enrolled
Vertigo, Peripheral
Company
Worked on DIMENHYDRINATE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.